BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRXGet Rating) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.04, Fidelity Earnings reports. During the same period in the previous year, the business earned ($0.24) earnings per share.

BioCryst Pharmaceuticals Trading Up 2.3 %

BCRX stock traded up $0.31 during trading on Friday, hitting $14.05. 6,071,737 shares of the stock traded hands, compared to its average volume of 2,781,210. BioCryst Pharmaceuticals has a one year low of $7.61 and a one year high of $19.99. The stock has a market cap of $2.61 billion, a price-to-earnings ratio of -12.22 and a beta of 2.20. The company has a 50 day simple moving average of $10.79 and a 200 day simple moving average of $12.78.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BCRX. Bank of America cut BioCryst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $21.00 to $14.00 in a research note on Monday, April 11th. Cantor Fitzgerald restated an “overweight” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, May 9th. Oppenheimer downgraded BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday. Royal Bank of Canada lowered their price objective on shares of BioCryst Pharmaceuticals from $16.00 to $14.00 and set a “sector perform” rating for the company in a research note on Tuesday, April 12th. Finally, StockNews.com raised shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. Eight research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Hold” and an average price target of $17.78.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently modified their holdings of BCRX. Fairfield Bush & CO. acquired a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter worth approximately $34,000. Lazard Asset Management LLC acquired a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at approximately $57,000. Point72 Hong Kong Ltd bought a new stake in shares of BioCryst Pharmaceuticals in the first quarter worth $118,000. Pearl River Capital LLC lifted its position in shares of BioCryst Pharmaceuticals by 33.3% in the first quarter. Pearl River Capital LLC now owns 45,155 shares of the biotechnology company’s stock worth $734,000 after purchasing an additional 11,275 shares in the last quarter. Finally, Verition Fund Management LLC bought a new stake in BioCryst Pharmaceuticals during the first quarter worth $252,000. 63.86% of the stock is owned by institutional investors.

About BioCryst Pharmaceuticals

(Get Rating)

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Featured Articles

Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.